EQL Pharma AB (EQL)

Currency in SEK
92.1000
-4.4000(-4.56%)
Closed·

EQL Financial Summary

Key Ratios

P/E Ratio63.82
Price/Book12.08
Debt / Equity206.17%
Return on Equity21.63%
Dividend Yield0.00%
EBITDA75.68M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2016
31/12
2017
31/12
2018
31/03
2019
31/03
2020
31/03
2021
31/03
2022
31/03
2023
31/03
2024
31/03
2025
31/03
* In Millions of SEK (except for per share items)

Earnings

Latest Release
Jul 25, 2025
EPS / Forecast
0.44 / 0.45
Revenue / Forecast
113.26M / 102.75M
EPS Revisions
Last 90 days

FAQ

What were EQL Pharma's earnings for the latest quarter?

The EQL Pharma EPS (TTM) is 1.48. EQL Pharma reported sales of 113.26, net income of 13.09, and EPS of 0.44 for the latest quarter.

What was EQL Pharma's net income for the latest quarter?

EQL Pharma's net income for the latest quarter was 13.09.

How did EQL Pharma's performance compare year-over-year in the latest quarter?

The company's revenue moved from 92.22 in the previous quarter to 113.26 in the latest quarter, and net income moved from 10.06 to 13.09 compared to the previous quarter.

What is EQL Pharma's net profit margin on a TTM basis?

EQL Pharma's trailing twelve months (TTM) net profit margin is 11.55%.

How does EQL Pharma's debt to equity ratio compare to industry standards?

EQL Pharma's total debt-to-equity ratio is 206.17%.

What is EQL Pharma's return on investment on a TTM basis?

EQL Pharma's trailing twelve months (TTM) return on investment (ROI) is 21.63%.

Did EQL Pharma gain or lose cash last quarter?

In the latest quarter, EQL Pharma's net change in cash was 66.84 million.

What were EQL Pharma's total assets and liabilities in the latest quarter?

As of the latest quarter, EQL Pharma reported total assets of 808.82 million and total liabilities of 221.02 million.

How has EQL Pharma's total revenue grown this year?

EQL Pharma's total revenue was 92.22 in the previous quarter and 113.26 in the latest quarter.

What is EQL Pharma's gross margin on a TTM basis?

EQL Pharma's trailing twelve months (TTM) gross margin is 41.75%.

What was EQL Pharma's revenue per share for the latest quarter?

EQL Pharma's revenue per share for the latest quarter was 324.69.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.